Corteva(CTVA) - 2025 Q4 - Earnings Call Transcript

Financial Performance - Corteva reported a strong year in 2025, with fourth-quarter results meeting expectations, except for stronger cash flow generation than anticipated [6] - The company achieved low single-digit top-line growth and low double-digit operating EBITDA growth, resulting in over 200 basis points of margin expansion, reaching over 22% for the first time as a public company [6][18] - Organic sales for the fourth quarter were down 4% year-over-year, with crop protection experiencing volume and price declines of 2% and 1% respectively [14][15] - For the full year, organic sales increased by 4%, with crop protection volume up 5% and seed price, mix, and volume gains of 3% and 2% respectively [16][18] Business Line Performance - The seed business showed organic growth in every region, with significant net cost improvements and royalty improvements, particularly in North America corn and Brazil soybean licensing [7][17] - The crop protection business also delivered growth and margin expansion, generating over $300 million in productivity and cost benefits [8][18] - The company expects to see modest growth in crop protection in 2026, despite competitive pricing dynamics in major markets [9][19] Market Insights - Overall agricultural fundamentals remain mixed, with record demand for food and fuel, and major crop inventories within normal ranges [8][9] - Farmers are prioritizing top-tier seed technologies while managing tighter margins, leading to a potential shift back to soybeans in 2026 [9][19] Strategic Direction - Corteva is on track for a separation in the second half of 2026, with ongoing preparations for executive leadership teams and capital structure submissions [4][5] - The company reached a resolution with Bayer regarding seed freedom to operate, which is expected to accelerate licensing opportunities and provide business certainty [10][11] - The resolution is anticipated to generate about $1 billion in aggregate earnings upside over the next decade through outlicensing and branded sales [12] Management Commentary - Management expressed confidence in the company's performance and outlook for 2026, reiterating a preliminary operating EBITDA midpoint of $4.1 billion, representing a 7% growth compared to the prior year [9][19] - The company is focused on controlling operational efficiencies and maintaining strong cash flow, with a commitment to returning cash to shareholders [23] Other Important Information - Free cash flow improved significantly to $2.9 billion, driven by increased EBITDA and working capital discipline [18][23] - The company plans to target approximately $500 million in share repurchases in the first half of 2026 [19] Q&A Session Summary Question: Can you break down the Bayer litigation impact? - Management highlighted that the agreement provides freedom to operate and increased access to the licensing market, accelerating corn licensing to as early as 2027 and entering the cotton licensing market [26][28] Question: Is there existing licensing expense that will no longer be incurred? - Management confirmed that a portion of the $120 million net royalty benefit in 2026 comes from Bayer royalties that will not be paid, leading to a net-neutral position two years ahead of expectations [33][34] Question: What is the status of Conkesta soybeans in Brazil? - Management indicated that they expect to double market share in 2026, transitioning to a focus on licensing through multipliers [61][64] Question: How do you view the productivity benefits for 2026? - Management stated that the $200 million productivity benefits are split equally between seed and crop protection, with ongoing opportunities for improvements [89]